Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Glucagon, an essential regulator of glucose homeostasis, also modulates lipid metabolism and promotes weight loss, as reflected by the wasting observed in glucagonoma patients. Recently, coagonist peptides that include glucagon agonism have emerged as promising therapeutic candidates for the treatment of obesity and diabetes. We developed a novel stable and soluble glucagon receptor (GcgR) agonist, which allowed for in vivo dissection of glucagon action. As expected, chronic GcgR agonism in mice resulted in hyperglycemia and lower body fat and plasma cholesterol. Notably, GcgR activation also raised hepatic expression and circulating levels of fibroblast growth factor 21 (FGF21). This effect was retained in isolated primary hepatocytes from wild-type (WT) mice, but not GcgR knockout mice. We confirmed this link in healthy human volunteers, where injection of natural glucagon increased plasma FGF21 within hours. Functional relevance was evidenced in mice with genetic deletion of FGF21, where GcgR activation failed to induce the body weight loss and lipid metabolism changes observed in WT mice. Taken together, these data reveal for the first time that glucagon controls glucose, energy, and lipid metabolism at least in part via FGF21-dependent pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that chronic GCG receptor agonism increased circulating FGF21 in mice and acute glucagon administration transiently increased FGF21 levels in humans25.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [25]
Citations
Cites
1 retracted
Berglund, E. D., Kang, L., Lee-Young, R. S., Hasenour, C. M., Lustig, D. G., Lynes, S. E., Donahue, E. P., Swift, L. L., Charron, M. J., & Wasserman, D. H. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00263.2010 · Cited by 100
RetractedFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · cited 1×
“Recent studies suggest that, like glucagon, FGF21 signaling regulates glucose, lipid, cholesterol, and bile acid metabolism (14,15), implicating FGF21 as an attractive drug candidate for metabolic disease.”
BackgroundSelf-citationInagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Disorders of motility and muscle tone with special reference to the corpus striatum
Wilson, S. A. K. (1925) · The Lancet · Cited by 1,409
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Self-citationThe metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · cited 2×
“FGF21 pharmacology reduces hyperglycemia, dyslipidemia, and plasma glucagon in diabetic mice and nonhuman primates (9).”
BackgroundSelf-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Cited by
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
Metabolism disrupting chemicals and metabolic disorders
Heindel, J. J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M. A., Nadal, A., Palanza, P., Panzica, G., Sargis, R., et al. (2017) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.10.001 · Cited by 1,101
Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Self-citationPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Self-citationGut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H.-R., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 297
Self-citationGlucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
“Previous studies have shown that chronic GCG receptor agonism increased circulating FGF21 in mice and acute glucagon administration transiently increased FGF21 levels in humans 25 .”
BackgroundFibroblast Growth Factor 21—Metabolic Role in Mice and Men
Staiger, H., Keuper, M., Berti, L., Hrabě de Angelis, M., & Häring, H.-U. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00016 · Cited by 270
Islet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Self-citationUnimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235
Self-citationTillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 213
“org 5 thyroid hormone signaling, since both activation of glucagon receptor (GCGR) (106) and thyroid hormone receptor-b (TR-b) (107) induce secretion of FGF21 by hepatocytes.”
BackgroundInventing new medicines: The FGF21 story
Kharitonenkov, A., & Adams, A. C. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.003 · Cited by 198
“While it was proposed that FGF21 may require an adipocyte specific co-factor [8], it took several years and various approaches to finally identify the transmembrane protein βKlotho (KLB) as the necessary co-receptor able to permit FGF21 mediated activation of FGFRs in vitro [22–25] and promote…”
BackgroundSelf-citationAction and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
“Keywords Oxyntomodulin; Glucagon; GLP-1; Glucose metabolism; Body weight”
BackgroundFinan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191
Self-citationEmerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12585 · Cited by 167
“Previous studies have suggested that glucagon stimulates FGF-21 secretion in humans [26] and that FGF-21 stimulates BAT.”
BackgroundFGF21-based pharmacotherapy – potential utility for metabolic disorders
Gimeno, R. E., & Moller, D. E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.03.001 · Cited by 163
Brown and Beige Adipose Tissues in Health and Disease
Rui, L. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170001 · Cited by 160
“Glucagon stimulates FGF21 secretion from the liver in both rodents and humans (10,112).”
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Self-citationFibroblast growth factor-21, energy balance and obesity
Giralt, M., Gavaldà‐Navarro, A., & Villarroya, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.018 · Cited by 161
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
“The half-life (t1/2) of acyl-glucagon is ~63 times longer compared to naïve glucagon (t1/2~5–6 min) [34].”
BackgroundInfluentialSelf-citationKim, K. H., & Lee, M.-S. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.4.245 · Cited by 146
The Biology of Glucagon and the Consequences of Hyperglucagonemia
Wewer Albrechtsen, N. J., Kuhre, R. E., Pedersen, J., Knop, F. K., & Holst, J. J. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0090 · Cited by 129
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 127
Circulating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio
Hansen, J. S., Rutti, S., Arous, C., Clemmesen, J. O., Secher, N. H., Drescher, A., Gonelle-Gispert, C., Halban, P. A., Pedersen, B. K., Weigert, C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3668 · Cited by 125
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Self-citationGlucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans
Hansen, J. S., Clemmesen, J. O., Secher, N. H., Hoene, M., Drescher, A., Weigert, C., Pedersen, B. K., & Plomgaard, P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.06.001 · Cited by 123
Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy
Itoh, N., Ohta, H., & Konishi, M. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00154 · Cited by 129
Self-citationRepositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Finan, B., Capozzi, M. E., & Campbell, J. E. (2020) · Diabetes · doi:10.2337/dbi19-0004 · Cited by 118
100 years of glucagon and 100 more
Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05947-y · Cited by 117
“…in rats but not in humans [68]), the rapid clearance of glucagon, dose-dependent interaction with the GLP-1 receptor [45], and direct vs indirect actions mediated by activation of the sympathetic nervous system or through secretion of hepatokines, such as fibroblast growth factor 21 (FGF21 [69]).”
BackgroundSelf-citationFGF21 activates AMPK signaling: impact on metabolic regulation and the aging process
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1477-1 · Cited by 127
Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes
Okun, J. G., Rusu, P. M., Chan, A. Y., Wu, Y., Yap, Y. W., Sharkie, T., Schumacher, J., Schmidt, K. V., Roberts-Thomson, K. M., Russell, R. D., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00369-9 · Cited by 116
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
Kharitonenkov, A., & DiMarchi, R. D. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.007 · Cited by 117
Self-citationMorville, T., Sahl, R. E., Trammell, S. A. J., Svenningsen, J. S., Gillum, M. P., Helge, J. W., & Clemmensen, C. (2018) · JCI Insight · doi:10.1172/jci.insight.122737 · Cited by 109
Hansen, J. S., Pedersen, B. K., Xu, G., Lehmann, R., Weigert, C., & Plomgaard, P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1681 · Cited by 106
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
Okamoto, H., Kim, J., Aglione, J., Lee, J., Cavino, K., Na, E., Rafique, A., Kim, J. H., Harp, J., Valenzuela, D. M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1011 · Cited by 100
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Kharitonenkov, A., & DiMarchi, R. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 100
Self-citationKim, T., Nason, S., Holleman, C., Pepin, M., Wilson, L., Berryhill, T. F., Wende, A. R., Steele, C., Young, M. E., Barnes, S., et al. (2018) · Diabetes · doi:10.2337/db17-1502 · Cited by 97
“Nonetheless, and consistent with our prior reports (5), BW reduction following GcgR agonism in DIO WT mice associated with an increase in light- and dark-phase EE (Figures 5a-b,e and S5a).”
BackgroundMethodResultInfluentialSelf-citationGong, M., Wen, S., Nguyen, T., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s232377 · Cited by 92
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Self-citationOng, K. L., Januszewski, A. S., O'Connell, R. L., Jenkins, A. J., Xu, A., SULLIVAN, D. R., Barter, P. J., Hung, W.-T., Scott, R. S., Taskinen, M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3458-7 · Cited by 93
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
Self-citationRoles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease
Itoh, N., Nakayama, Y., & Konishi, M. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00030 · Cited by 92
“Findings obtained from FGF21 knockout mice suggest that hepatic FGF21 contributes, at least in part, to glucose, energy, and lipid metabolism controlled by glucagon (Habegger et al., 2013).”
BackgroundSelf-citationGlucagon Control on Food Intake and Energy Balance
Al-Massadi, O., Fernø, J., Diéguez, C., Nogueiras, R., & Quiñones, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163905 · Cited by 88
Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Stern, J. H., Campbell, J. E., Scherer, P. E., & Drucker, D. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.011 · Cited by 88
Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
Martínez‐Garza, Ú., Torres‐Oteros, D., Yarritu, A., Marrero, P. F., Haro, D., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194692 · Cited by 96
Gilroy, C. A., Capozzi, M. E., Varanko, A. K., Tong, J., D'Alessio, D. A., Campbell, J. E., & Chilkoti, A. (2020) · Science Advances · doi:10.1126/sciadv.aaz9890 · Cited by 85
Self-citationLeveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
Self-citationMa, Z., Deng, C., Hu, W., Zhou, J., Fan, C., Di, S., Liu, D., Yang, Y., & Wang, D. (2017) · Current Issues in Molecular Biology · doi:10.21775/cimb.022.041 · Cited by 70
Lawan, A., Zhang, L., Gatzke, F., Min, K., Jurczak, M. J., Al-Mutairi, M., Richter, P., Camporez, J. P. G., Couvillon, A., Pesta, D., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00503-14 · Cited by 84
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 96
Self-citationStriking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
“Circulating FGF-21 has also been implicated in energy expenditure effects with chronic glucagon agonism, as Fgf21 knock-out mice are protected from these effects (57).”
BackgroundCirculating FGF21 Levels in Human Health and Metabolic Disease
Keuper, M., Häring, H., & Staiger, H. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0879-2968 · Cited by 86
“Injecting native glucagon in healthy, obese individuals increased circulating FGF21 levels [83], thus providing evidence for a muscle-pancreas-liver axis that plays a role in exercise-induced elevation of FGF21 blood levels.”
BackgroundFinan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81
Self-citationThe molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Self-citationCyphert, H. A., Alonge, K. M., Ippagunta, S. M., & Hillgartner, F. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094996 · Cited by 79
Fibroblast activation protein (FAP) as a novel metabolic target
Sánchez-Garrido, M. A., Habegger, K. M., Clemmensen, C., Holleman, C., Müller, T. D., Perez-Tilve, D., Li, P., Agrawal, A. S., Finan, B., Drucker, D. J., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.07.003 · Cited by 79
Self-citationAmbery, P. D., Klammt, S., Posch, M. G., Petrone, M., Pu, W., Rondinone, C., Jermutus, L., & Hirshberg, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13688 · Cited by 75
Role of Glucagon in Catabolism and Muscle Wasting of Critical Illness and Modulation by Nutrition
Thiessen, S. E., Derde, S., Derese, I., Dufour, T., Vega, C. A., Langouche, L., Goossens, C., Peersman, N., Vermeersch, P., Vander Perre, S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0354oc · Cited by 75
Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents
Kim, T., Holleman, C. L., Nason, S., Arble, D. M., Ottaway, N., Chabenne, J., Loyd, C., Kim, J.-A., Sandoval, D., Drucker, D. J., et al. (2018) · Diabetes · doi:10.2337/db18-0068 · Cited by 68
“Likewise, we have reported that GCGR-agonism induces the expression and secretion of FGF21, a known insulin sensitizer(11).”
InfluentialSelf-citationLack of glucagon receptor signaling and its implications beyond glucose homeostasis
Charron, M. J., & Vuguin, P. M. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0614 · Cited by 68
“…lipid metabolism at least in part via AC/cAMP-independent signals including p38MAPK, IP3/DAG/Ca, peroxisome proliferator-activated receptor alpha (PPARa), and fibroblast growth factor 21 (FGF21)dependent pathways (Berglund et al. 2010, Habegger et al. 2010, 2013, Rodgers 2012, Cyphert et al. 2014).”
Glucagon Is Essential for Adaptive Thermogenesis in Brown Adipose Tissue
Kinoshita, K., Ozaki, N., Takagi, Y., Murata, Y., Oshida, Y., & Hayashi, Y. (2014) · Endocrinology · doi:10.1210/en.2014-1175 · Cited by 66
Lips, M. A., de Groot, G. H., Berends, F. J., Wiezer, R., van Wagensveld, B. A., Swank, D. J., Luijten, A., van Dijk, K. W., Pijl, H., Jansen, P. L. M., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12496 · Cited by 64
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 65
Self-citationFGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs
Kim, K. H., & Lee, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0160 · Cited by 71
“The effects of glucagon agonism inducing body weight loss, hypocholesterolemia, and increased energy expenditure were lower in Fgf21K/K mice than in control mice (Habegger et al. 2013).”
BackgroundNewly discovered endocrine functions of the liver
Rhyu, J., & Yu, R. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1611 · Cited by 76
A link between hepatic glucose production and peripheral energy metabolism via hepatokines
Abdul-Wahed, A., Gautier-Stein, A., Casteras, S., Soty, M., Roussel, D., Romestaing, C., Guillou, H., Tourette, J.-A., Pleche, N., Zitoun, C., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.05.005 · Cited by 62
Struik, D., Dommerholt, M. B., & Jonker, J. W. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000599 · Cited by 61
Jun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W. (2015) · Diabetes · doi:10.2337/db14-1052 · Cited by 60
Glucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive Physiology · doi:10.1002/cphy.c200013 · Cited by 59
“Interestingly, chronic Gcgr agonism in lean male mice stimulates hyperphagia and a defense of their body weight (145), most likely to offset the increase in energy expenditure.”
InfluentialSelf-citationHepatic glucagon action: beyond glucose mobilization
Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 71
Regulation of amino acid metabolism and α‐cell proliferation by glucagon
Hayashi, Y., & Seino, Y. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12797 · Cited by 59
Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes
Marroquí, L., Alonso-Magdalena, P., Merino, B., Fuentes, E., Nadal, A., & Quesada, I. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000031 · Cited by 54
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Roh, E., & Choi, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043384 · Cited by 66
Rajas, F., Labrune, P., & Mithieux, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.002 · Cited by 60
“[126] Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, Ottaway N, et al.”
BackgroundInfluentialThe regulation of FGF21 gene expression by metabolic factors and nutrients
Erickson, A., & Moreau, R. F. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0016 · Cited by 64
Glucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49
Nonogaki, K., Hazama, M., & Satoh, N. (2014) · BioMed Research International · doi:10.1155/2014/751930 · Cited by 50
“Native glucagon increases plasma Fgf21 levels in human subjects [21], and a synthetic glucagon receptor agonist (IUB288) upregulates Fgf21 expression in isolated primary hepatocytes from mice [22].”
BackgroundEffect of exercise intensity on circulating hepatokine concentrations in healthy men
Willis, S. A., Sargeant, J. A., Thackray, A. E., Yates, T., Stensel, D. J., Aithal, G. P., & King, J. A. (2019) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2018-0818 · Cited by 48
Loyd, C., Magrisso, I. J., Haas, M., Balusu, S., Krishna, R., Itoh, N., Sandoval, D. A., Perez-Tilve, D., Obici, S., & Habegger, K. M. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00456.2016 · Cited by 46
Self-citationIs Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
Conceição-Furber, E., Coskun, T., Sloop, K. W., & Samms, R. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.868037 · Cited by 48
“org 3 Preclinically, the robustness of glucagon’s thermogenic activity is exemplified by its ability to increase energy expenditure across multiple species, including mice, rats, penguins, pigs, and dogs [see Figure 1 (59–62)], and by findings showing that the administration of glucagon reduces body weight in already…”
BackgroundInfluentialHepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21
Camporez, J. P. G., Asrih, M., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., & Jornayvaz, F. R. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0136 · Cited by 44
“…glucagon might be a compensatory mechanism to increase FGF21 concentrations, as recent findings reported that glucagon increases FGF21 levels (Arafat et al. 2013), further mediating glucagon actions (Habegger et al. 2013), but these considerations remain speculative, as we have no direct evidence.”
BackgroundAliakbarian, H., Bhutta, H. Y., Heshmati, K., Unes Kunju, S., Sheu, E. G., & Tavakkoli, A. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04877-7 · Cited by 43
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
Lin, X., He, X., Zeng, J., Zhang, H., Zhao, Y., Tan, J.-K., & Zuo, W. (2014) · DNA and Cell Biology · doi:10.1089/dna.2013.2290 · Cited by 42
“Several studies have analyzed the role of FGF21 in glucose and lipid metabolism (Habegger et al. , 2013; Li et al. , 2013).”
Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte
Habegger, K. M. (2022) · Diabetes · doi:10.2337/dbi22-0002 · Cited by 44
Self-citationContemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Kalra, S., Bhattacharya, S., & Kapoor, N. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01113-y · Cited by 38
Fève, B., Bastard, C., Fellahi, S., Bastard, J., & Capeau, J. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.01.001 · Cited by 47
Heilbronn, L. K., Campbell, L. V., Xu, A., & Samocha-Bonet, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078864 · Cited by 36
Glucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
Glucagon receptor signaling regulates weight loss via central KLB receptor complexes
Nason, S. R., Antipenko, J., Presedo, N., Cunningham, S. E., Pierre, T. H., Kim, T., Paul, J. R., Holleman, C., Young, M. E., Gamble, K. L., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141323 · Cited by 34
“Concordant with our previous observations (13, 14, 39), chronic IUB288 administration stimulated robust weight loss in control mice ( P < 0.0001, % change from day 0, Figure 3A; and body weight change in grams,”
InfluentialSelf-citationRegulation of thermogenic adipocytes during fasting and cold
Reinisch, I., Schreiber, R., & Prokesch, A. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110869 · Cited by 36
Hepatic Glucagon Receptor Signaling Controls Amino Acid Metabolism and Regulates Alpha Cell Mass
Elmelund, E., Galsgaard, K. D., Johansen, C. D., Trammell, S. A. J., Bomholt, A. B., Winther‐Sørensen, M., Hunt, J. E., Sørensen, C. M., Kruse, T., Lau, J. F., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105296 · Cited by 33
“…by these dual agonists (Tillner et al., 2019; Ambery et al., 2018; Pocai et al., 2009; Day et al., 2009), and chronic glucagon receptor activation, using a long-acting agonist, also resulted in weight loss and decreased food intake (Habegger et al., 2013; Kim et al., 2018; Nason et al., 2021).”
BackgroundFGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk
CHAFFIN, A. T. B., Larson, K. R., Huang, K.-P., Wu, C.-T., Nadejda, G., Fang, Y., Jayakrishnan, D., Sauza, K. A. S., Sims, L. C., Mohajerani, N., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155848 · Cited by 32
Yang, P., Zou, H., Amso, Z., Lee, C., Huang, D., Woods, A. K., Nguyen-Tran, V. T. B., Schultz, P. G., & Shen, W. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00093 · Cited by 33
Metadata
- Authors
- Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., Krishna, R., Arafat, A. M., Konkar, A., Belli, S., Kapps, M., Woods, S. C., Hofmann, S. M., D’Alessio, D., Pfluger, P. T., Perez-Tilve, D., Seeley, R. J., Konishi, M., Itoh, N., Kharitonenkov, A., Spranger, J., DiMarchi, R. D., & Tschöp, M. H.
- Affiliations
- University of Cincinnati (US)
- Helmholtz Munich (DE)
- Eli Lilly (United States) (US)
- Indiana University Bloomington (US)
- Charité – Universitätsmedizin Berlin (DE)
- F. Hoffmann-La Roche AG (CH)
- Metabolic Disease Institute, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio
- Kyoto University (JP)
- Corresponding author
- Tschöp, Matthias H.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-04-16
- Volume
- 62
- Issue
- 5
- Pages
- 1453-1463
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3636653
- OpenAlex
- W2131192628
- Cited by
- 245
- References
- 38
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 21 · 2023: 15 · 2022: 17 · 2021: 19 · 2020: 16 · 2019: 16 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 27 · 2014: 22 · 2013: 12
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- F. Hoffmann-La Roche
- University of Cincinnati
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, glucagon, glucagon receptor agonist, glucose homeostasis, lipid metabolism, weight loss, hyperglycemia, obesity, serum cholesterol, energy metabolism
- MeSH terms
- Adult, Animals, Cells, Cultured, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Fibroblast Growth Factors, Glucagon, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Mice, Mutant Strains, Obesity, Peptides, Recombinant Proteins, Receptors, Glucagon, Mice, Knockout, Cross-Over Studies, Anti-Obesity Agents, Hepatocytes, Mice, Rats, HEK293 Cells, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.